Could a Diabetes Drug Help Save Legs, Not Just Hearts? New…

Could a Diabetes Drug Help Save Legs, Not Just Hearts? New Data Says Yes Peripheral artery disease affects over 236 million people worldwide, and it's particularly common and severe in people with type 2 diabetes. Yet treatment options that directly protect limbs, not just the heart, have remained frustratingly limited. A new large-scale study published in the Journal of the American Heart Association suggests GLP-1 receptor agonists, the same class of drugs behind Ozempic and Wegovy, may fill exactly that gap. Researchers at Cleveland Clinic analysed real-world data from over 8,000 patients with both peripheral artery disease and type 2 diabetes, comparing those treated with GLP-1 receptor agonists against those treated with metformin. After carefully matching patients to balance out other differences, they tracked outcomes over 5 years. Patients on GLP-1 receptor agonists had significantly lower rates of: Death — 10.3% versus 14.5% Hospitalisation — 69.3% versu